Treatment of Pseudomonas Pneumonia

Introduction to Meropenem Therapy

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) recommend meropenem 1 g IV every 8 hours for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) where Pseudomonas is a concern 1, 2
Meropenem should be administered at a dose of 1 gram intravenously every 8 hours for Pseudomonas pneumonia, as recommended by multiple guidelines 1, 2, 3
This dosing is specifically indicated for patients at high risk of multidrug-resistant pathogens or with unstable hemodynamics 3

For severe Pseudomonas pneumonia, especially in critically ill patients, consider combination therapy with an aminoglycoside or fluoroquinolone for synergistic effect 2, 3
Combination therapy may be particularly important for patients with septic shock, high risk of mortality, or concern for multidrug-resistant strains 2, 3

The duration of meropenem therapy is typically 7-14 days, based on clinical response 4

The efficacy of meropenem against Pseudomonas depends on maintaining concentrations above the MIC, with a target of at least 40% of the dosing interval 1, 2, 3
Inadequate dosing may lead to treatment failure and emergence of resistance, highlighting the importance of proper dosing and adjustment for renal function 1, 2, 3